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Abstract
Multiple myeloma (MM) is associated with increased risk of infection, but little is known regarding antibody levels
against specific bacteria. We assessed levels of polyclonal immunoglobulin and antibacterial antibodies in patients
recruited to the TEAMM trial, a randomised trial of antibiotic prophylaxis at the start of anti-myeloma treatment.
Polyclonal IgG, IgA and IgM levels were below the reference range in 71%, 83% and 90% of 838 MM patients at
diagnosis. Anti-vaccine targeted tetanus toxoid antibodies were protective in 95% of 193 healthy controls but only
41% of myeloma patients. In healthy controls, protective antibodies against 6/12 pneumococcal serotypes,
haemophilus and meningococcus A were present in 67%, 41% and 56% compared to just 15%, 21% and 17% of
myeloma patients. By 1 year, myeloma patients IgG levels had recovered for 57% of patients whilst the proportion with
protective levels of IgG against thymus-dependent protein antigen tetanus toxoid had changed little. In contrast the
proportions of patients with protective levels against thymus independent polysaccharide antigens pneumococcus,
haemophilus and meningococcus had fallen from 15 to 7%, 21 to 0% and 17 to 11%. Findings highlight the need for
strategies to protect patients against bacterial infections during therapy and vaccination programmes during
remission.
Introduction
Multiple myeloma (MM) arises from the malignant
proliferation of a single clone of plasma cells in the bone
marrow and accounts for over 10% of haematological
malignancies1–3. With the average age at diagnosis being
70 years MM causes anaemia, skeletal fractures, renal
failure and profound cellular and humoral immunodefi-
ciency1–3. Advances in anti-myeloma therapy have
improved overall survival (OS) to 50% at 5 years but
infection contributes to death in a fifth of patients with
myeloma1,2,4–7. The risk of infection is greatest in the first
3 months after diagnosis, with a third of patients suffering
serious bacterial infection, and infection contributing to
half of early mortality8–10. The most common causes of
infection are encapsulated extracellular bacteria such as
Streptococcus pneumoniae and Haemophilus influenza8.
Although novel agents and intensive therapeutic strate-
gies have improved survival rates for myeloma, anti-
myeloma therapy may further suppress patient’s immu-
nological functions7.
Humoral immunodeficiency in MM is characterised by
polyclonal IgM, IgG and IgA levels below the normal
range in 85% of patients (immunoparesis)11–13. Lower
levels of polyclonal IgG and IgA have been reported to be
predictive of blood stream infections in the first few
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months from MM diagnosis and serious infection epi-
sodes during MM remission14,15. However, Danish reg-
istry analysis of 2557 MM patients during 6 months from
diagnosis showed tumour burden and renal impairment
but not immunoparesis were risk factors for infection16.
The level of suppression of polyclonal immunoglobulin
in patients is inversely correlated with the level of M-
protein and with MM stage, indicating increased sup-
pression is identified in more aggressive forms of dis-
ease12,13,17. In recent UK myeloma trials median
progression-free survival (PFS) was 57%, 39% and 36%
longer for patients with normal IgM, IgG and IgA levels,
respectively12. The depth of IgM suppression, but not the
depth of IgG or IgA suppression, was prognostic for
survival: the most severely suppressed IgM tertile of
patients OS was 0.9 years shorter than those in the top
tertile, and 2.6 years shorter than OS of those with normal
IgM levels
Much is known about the significance of total levels of
polyclonal immunoglobulins in MM with respect to sur-
vival but as we have found they are not strongly predictive
of infection12. To our knowledge, the significance of
antibody levels specific to different bacterial antigenic
targets at diagnosis and following modern MM therapies
has yet to be characterised. A clear picture of patients’
immunological status may help stratify them for risk of
specific infections during induction therapy and may be of
prognostic value for OS and PFS. Also, understanding the
timeframe of immunoglobulin recovery may have an
impact on the clinical management of patients.
We assessed polyclonal immunoglobulin levels and
those directed against pertinent bacterial antigens at dis-
ease presentation and after 1 year in a large patient
population from the UK Tackling-Early-Morbidity-and-
Mortality-in-Myeloma (TEAMM) trial that had been
designed to investigate the effect of antibiotic prophylaxis
on infections and deaths18.
Methods
TEAMM Trial and patients
The TEAMM trial was a multicentre randomised,
double-blind, placebo-controlled trial in newly diagnosed
myeloma patients randomised to receive Levofloxacin or
placebo for 12 weeks at the start of anti-myeloma treat-
ment. Follow-up was 4-weekly to 16 weeks and again at 1
year. The primary outcome was time to first febrile epi-
sode or death in the first 12 weeks from start of trial
treatment. Secondary outcomes included number of
infections, deaths, healthcare-associated organism car-
riage and invasive infections, and OS18.
The TEAMM trial recruited between August 2012 and
April 2016, 977 patients aged ≥21 years with newly
diagnosed symptomatic myeloma, and within 14 days of
starting active myeloma treatment. Treatment allocation
was blinded and balanced by centre, estimated glomerular
filtration rate (eGFR) and intention to give high-dose
chemotherapy with autologous stem cell transplant. The
838 included in the present investigation out of 977
patients in the trial represent patients with sufficient
serum sample available for analysis. Details of treatment,
however, are limited to intended treatments at baseline as
the trial did not record treatment delivered, with the
exception of steroid usage. The trial (ISRCTN registration
No. 51731976) had approval from the UK Coventry &
Warwickshire Multi-Research Ethics Committee and all
patients provided written informed consent. Serum sam-
ples from 193 healthy adult donors for determining adult
ranges for the assays were from NHS Blood and Trans-
plant, Birmingham, UK (NHSBT; age range 17–65 years).
Laboratory analysis
Serum from diagnosis was analysed centrally at the
Clinical Immunology Service (Birmingham, UK) by pro-
tein electrophoresis, densitometry and immunofixation
for M-protein quantification and characterisation. Serum
IgG, IgA and IgM, and kappa and lambda free light chains
(sFLC) levels were quantified by turbidimetry. Patients
were characterised as having one of the following multiple
myelomas: IgG, IgA, IgM, IgD, light chain only (LCO),
non-secretory (NS) or oligosecretory; with either kappa or
lambda monoclonal light chain. Patients were classified as
being below, within or above normal range (NR) for
polyclonal immunoglobulins based upon 5th–95th centile
ranges of adults aged over 45 years in the UK reported by
Protein Reference Units: IgG 6–16 g/l; IgA 0.8–4 g/l; and
IgM 0.5–2 g/l.
The serum from 838 MM patients (aged 35–90)
enrolled in the TEAMM trial was analysed at disease
presentation and after 1 year from first trial visit. The
concentration of 19 anti-bacterial antibodies were quan-
tified using a multiplexed Luminex assay, described in
detail previously19. IgG antibody levels were measured
against 12 pneumococcal (Pn) serotypes, 4 meningococcal
(Men) serotypes, Haemophilus influenzae type b (Hib)
polysaccharide, and tetanus and diphtheria toxoids. Pro-
tective thresholds for IgG were: 0.35 μg/ml for Pn ser-
otypes20, 2 μg/ml for Men serotypes21, 1 μg/ml for Hib
polysaccharide22, and 0.1 IU/ml for diphtheria and teta-
nus23. Streptococcus pneumoniae capsular polysaccharides
were obtained from the American Type Culture Collec-
tion (Manassas, Virginia, USA), Tetanus toxoid was
obtained from Quadratech (Epsom, UK), Neisseria
meningitidis and Hib capsular polysaccharides, and
diphtheria toxoid were from the National Institute for
Biological Standards and Control (Potters Bar, UK).
Briefly, polysaccharide antigens were pre-conjugated to
poly-L-lysine (Sigma-Aldrich, Darmstadt, Germany) and
purified. Poly-L-lysine-conjugated antigens and toxoids
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were conjugated to carboxylated microspheres (Bio-plex
Systems, BioRad Laboratories, Hercules, California, USA),
each corresponding to a different bead region, through a
two-steps carbodiimide reaction. Beads were resuspended
in phosphate-buffered saline (PBS) 0.1% Bovine Serum
Albumin (BSA), 0.05% sodium azide, counted with a
haemocytometer and stored in the dark at 4 °C. The
analysis of serum samples for 19 antigens (19-plex) on
multi-beads was performed in a 96-well filter plate. A 12
point standard curve was obtained following a 12-fold 1:2
dilution of standard serum 007 in PBS 1% BSA 0.05%
Tween 20 containing 5 µg/ml pneumococcal cell wall
polysaccharide (Statens Serum Institute, Copenhagen,
Denmark). Serum samples were diluted 1:100 using PBS
1% BSA 0.05% Tween containing 5 µg/ml pneumococcal
cell wall polysaccharide and 5 µg/ml pneumococcal ser-
otype 22 F to prevent unspecific binding. Human serum,
pooled serum and serum deprived of IgGs were used as
controls. In all, 200 µl of PBS 0.05% Tween 20 were
aspirated through the filter of each well to pre-wet the
filter. Twenty-five microlitres of bead-conjugated anti-
body mix were added to each well and washed twice with
PBS 0.05% Tween 20. Twenty-five microlitres of test
samples were added to the plate and incubated at room
temperature covered from light for 1 h on an orbital
shaker at 500 rpm. After washing, 100 µl of mouse anti-
human IgG phycoerythrin-conjugated antibody (Southern
Biotech, Birmingham, Alabama, USA) diluted 1:200 were
added and left in incubation at room temperature covered
from light for 30min on an orbital shaker at 500 rpm.
Wells were washed twice and beads were resuspended in
125 µl PBS 0.05% Tween 20 for the reading. Fluorescent
intensity was measured with a Luminex-200 instrument
(BioRad Laboratories) and data analysis was performed
with Bio-plex Manager 6.1 software (BioRad Labora-
tories). Polyclonal IgG, IgA and IgM were quantified by
turbidimetry. Antibody levels in patients with MM were
compared to a cohort of 193 healthy adult blood trans-
fusion service donors19.
Statistical analysis
Statistical analyses were performed using Prism v.
8 software (GraphPad, San Diego, California, USA) and
SAS® (version 9.3; SAS Institute Inc., Cary, NC, USA)
software. Statistical significance of the results was deter-
mined using the Chi-Square test to identify differences in
categorical variables between groups, Wilcoxon’s rank test
to compared differences between paired data and the
Mann–Whitney test or Kruskal–Wallis test to analyse
differences between unpaired data. Correlations between
biomarkers and outcomes measures were investigated
using Spearman’s rank test. Infection rates and febrile
episodes were investigated based on severity of polyclonal
immunoglobulin suppression. Patients were split into
groups based on normal, slightly reduced and severely
reduced polyclonal immunoglobulins. Incidence of
infection (yes/no) or febrile episode (yes/no) in the first
12 weeks was compared between groups polyclonal
immunoglobulin groups using Fisher’s exact test.
Analysis of time to first infection within 12 weeks was
carried out using a log-rank comparison, starting from the
date the patient started trial treatment to the date of
infection, or to a censor date for those with no infections.
Cox regression analyses were performed to determine
independent predictors of febrile episode or death. Patient
and disease characteristics were considered, including
polyclonal IgM, polysaccharide antigens, tetanus and
diphtheria toxoids. Overall survival was calculated from
date of starting trial treatment to the date of death or
censor date for those alive up to 12 months.
In addition to TEAMM treatment allocation (Levo-
floxacin or placebo), prophylactic Septrin was evaluated as
an independent predictor of febrile episode or death.
Patients were ineligible for the TEAMM trial if receiving
other prophylactic antibiotic treatment, excluding pneu-
mocystis prophylaxis if regarded as essential. Prophylactic
co-trimoxazole 960mg (Septrin) three times per week to
prevent pneumocysistis was allowed and given to 314
patients within the TEAMM trial due to its wide use in
the UK but was not part of stratification or randomisation.
Results of the TEAMM trial showed a benefit in reducing
febrile episodes for patients taking septrin prophylaxis, a
benefit for levofloxacin prophylaxis and the greatest
benefit for patients who took both antibiotics as prophy-
laxis compared to the population receiving no antibiotic
prophylaxis.
Results
Patient characteristics
At entry to the trial patients were stratified according to
intention to treat intensively with an autologous stem cell
rescue procedure (transplant eligible TE) or for older
frailer patients to receive non-intensive therapy (Trans-
plant non-eligible TNE)24. Patient characteristics are
presented in Table 1 split by intention to give intensive
treatment (456 TE patients) or not (380 TNE patients).
TE patients were younger, had better performance status,
renal function and earlier stage myeloma disease. There
was no difference in neutrophil counts with 9% having
levels <1.8 × 109/l but lymphopaenia (<1.2 × 109/l) was
commoner in TNE patients. 99% of all patients treatment
included an immunomodulatory drug or proteasome
inhibitor as anti-myeloma therapy and bisphosphonates.
Polyclonal immunoglobulin levels are low at MM diagnosis
and recover significantly by 1 year
Serum polyclonal IgG, IgA and IgM were measured
in TEAMM patients without an IgG, IgA and IgM
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Table 1 Patient characteristics by intention to give intensive treatment.
Intention to give intensive treatment
No
n= 380
Yes
n= 456
Total
n= 836
Factor Grouping N % N % N %
Age (years) Median (IQR) 75 (70–79) 61 (54–66) 67 (60–75)
Gender Male 236 62 293 64 529 63
Female 144 38 163 36 307 37
Ethnicity White 356 94 412 90 768 92
Mixed 1 <1 2 <1 3 <1
Asian or British Asian 3 1 17 4 20 2
Black or Black British 20 5 23 5 43 5
Chinese or Other 0 0 1 <1 3 <1
Missing 0 0 1 <1 1 <1
Performance 0 91 24 201 44 292 35
status at 1 170 45 169 37 339 41
Randomisation 2 80 21 54 12 134 16
3 27 7 24 5 51 6
4 1 <1 3 1 4 <1
Missing 11 3 5 1 16 2
International Staging Stage I 64 17 121 26 185 22
System Stage II 117 31 182 40 299 36
Stage III 125 33 99 22 224 27
Missing 74 19 54 12 128 15
eGFR >50 ml/min 246 65 381 84 627 75
20–50 ml/min 101 26 64 14 165 20
<20 ml/min 33 9 11 2 44 5
Prior infection Clostridium-Difficile 2 1 1 <1 3 <1
MRSA 6 2 5 1 11 1
ESBL coliforms 2 1 6 1 8 1
Anti-infectives No 237 63 323 71 560 67
in month prior Yes 62 16 72 16 134 16
Missing 81 21 61 13 142 17
Steroids 14 days prior to randomisation Yes 180 47 243 53 423 51
Corticosteroids Prednisolone 23 6 11 2 34 4
Dexamethasone 158 42 234 51 392 47
Other 1 <1 1 <1 2 <1
Planned anti-myeloma Thalidomide based 185 49 178 39 363 43
treatment Bortezomib based 120 32 146 32 266 32
Lenalidomide based 64 17 57 13 121 14
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Table 1 continued
Intention to give intensive treatment
No
n= 380
Yes
n= 456
Total
n= 836
Factor Grouping N % N % N %
Lenalidomide & Carfilzomib based 3 1 71 16 74 9
Other 8 2 4 1 12 1
Bisphosphonate Not given 65 17 39 9 104 12
Status at Given/will be given 313 82 414 91 727 87
Randomisation Missing 2 1 3 1 5 1
Bisphosphonate Zolendronate 194 51 293 64 487 58
Pamidronate 94 25 96 21 190 23
Clodronate 19 5 14 3 33 4
Other 3 1 5 1 8 1
Missing 70 18 48 11 118 14
Prophylactic anti- No 209 55 205 45 414 50
viral/fungal Yes 171 45 251 55 422 50
Corrected calcium <2.5 273 72 317 70 590 70
(μmol/l) 2.5–2.75 78 20 97 21 175 21
>2.75 15 4 33 7 48 6
Missing 14 4 9 2 23 3
Evidence of bone disease Yes 265 70 336 74 601 72
Site of bone disease Vertebral fracture/collapse 115 30 114 25 229 27
Lytic lesions 180 47 238 52 418 50
Fractured rib 22 6 27 6 49 6
Osteoporosis 38 10 23 5 61 7
Other fracture 28 7 44 10 72 9
Sb2m (mg/l) ≤4 111 29 216 47 327 39
4–8 119 31 139 30 258 31
>8 76 20 48 11 124 15
Missing 74 20 53 12 127 15
Anaemia (Hb g/dl) <7.5 11 3 9 2 20 2
7.5–10 144 38 137 30 281 34
>10 221 58 310 68 531 64
Missing 4 1 0 0 4 <1
Thrombocytopenia ≤150 63 17 62 14 125 15
(platelets x109/l) >150 313 82 393 86 706 84
Missing 4 1 1 <1 5 1
Neutrophils (x109/l) <1.8 36 9 39 9 75 9
1.8 to 3 106 28 132 29 238 28
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M-protein, respectively, at disease diagnosis and at 1 year.
Polyclonal IgG, IgA and IgM levels were below the
reference range (RR) in 71%, 83 and 90% of 838 MM
patients at diagnosis (Fig. 1). In 196 patients with paired
polyclonal IgG levels at baseline and 1 year the proportion
of patients with levels within the RR increased from 25 to
57%, with median levels increasing from 4.4 to 6.6 g/l. For
405 patients with paired polyclonal IgA levels the increase
by 1 year was from 15 to 33% with median levels
increasing from 0.3 to 0.6 g/l. For 513 patients with paired
polyclonal IgM levels at both time-points the increase in
proportion with levels within the RR was from 10% at
diagnosis to 21% at 1 year with median levels increasing
from 0.2 to 0.3 g/l (Fig. 1). These increases in polyclonal
immunoglobulin levels between diagnosis and 1 year
occurred in both patients who were transplant eligible
(TE) and transplant non-eligible (TNE) with no significant
difference between the two cohorts (p= .55 for IgG,
Table 1 continued
Intention to give intensive treatment
No
n= 380
Yes
n= 456
Total
n= 836
Factor Grouping N % N % N %
>3 232 61 284 62 516 62
Missing 6 2 1 <1 7 1
Lymphocytes <1.2 104 27 104 23 208 25
1.2–1.8 252 66 336 74 588 70
>1.8 18 5 15 3 33 4
Missing 6 2 1 <1 7 1
Serum creatinine <130 268 71 392 86 660 79
(μmol/l) 130–199 61 16 34 7 95 11
>199 46 12 27 6 73 9
Missing 5 1 3 1 8 1
Fig. 1 Levels of polyclonal IgG, IgA and IgM in healthy controls and TEAMM patients without an IgG, IgA and IgM M-protein, respectively,
at diagnosis and 1 year post-diagnosis. Distribution of polyclonal antibody quantified in a healthy cohort and TEAMM patients without an IgG, IgA
and IgM M-protein, respectively, at disease presentation (baseline) and at 1 year post diagnosis. The median line for each cohort is shown in black
while the 5th and 95th centile of polyclonal normal range (IgG: 6 g/l and 16 g/l; IgA: 0.8 g/l and 4 g/l; IgM: 0.5 g/l and 2 g/l) are represented as
discontinuous lines. Statistical significance was calculated using the Wilcoxon and the Mann–Whitney tests and is shown for each pair of data (***p< 0.001,
###p < 0.001).
Chicca et al. Blood Cancer Journal          (2020) 10:114 Page 6 of 12
Blood Cancer Journal
p= 0.57 for IgM and p= 0.78 for IgA (Fig. S1)). Similarly,
when we split patients according to whether they were
randomised to levofloxacin or placebo there was no dif-
ference in the increases in polyclonal immunoglobulin
levels between diagnosis and 1 year (data not shown). For
all three types of polyclonal immunoglobulins median
levels in TEAMM patients at all time-points were sig-
nificantly lower than median levels identified in the
healthy cohort (Fig. 1).
Severely reduced polyclonal immunoglobulins are
associated with higher infection rates
Infection rates and febrile episodes were analysed
according to degree polyclonal immunodeficiency (normal,
slightly reduced and severely reduced) and are reported in
Table S1. There was no difference in incidence of infections
or febrile episodes based on degree of polyclonal IgG
deficiency. Infections and febrile episodes were more likely
to occur (p < 0.05) in patients with severely reduced poly-
clonal IgA (47% and 26% of patients, respectively) vs.
normal polyclonal IgA (35% and 16% of patients,
respectively). Similarly, incidence of infection was sig-
nificantly associated with severely reduced polyclonal IgM
(48%) vs. normal IgM (36%), p < 0.01; febrile episodes also
occurred more frequently in patients with severely (23%)
and slightly (22%) reduced polyclonal IgM compared to
those with normal IgM levels (15%), p < 0.05.
Anti-bacterial IgG antibody levels are very low at MM
diagnosis
At diagnosis median levels of total polyclonal IgG are
4.4 g/l (43%) compared to 10.2 g/l for healthy controls.
Figure 2 shows the proportions of heathy volunteers and
myeloma patients that have IgG antibody levels above
protective thresholds for 19 bacterial antigen targets (12
pneumococcal serotypes, 4 meningococcal serotypes,
haemophilus, tetanus and diphtheria toxoids). Figure 3
shows the specific antibody levels for these 838 patients.
The mean percentage of the 838 MM patients at diagnosis
with protective IgG antibody levels against any one of the
19 bacterial antigen targets was 20% compared to 55% of
the 193 healthy controls. Of the pneumococcal serotypes,
Fig. 2 Percentage of individuals with protective levels of anti-bacterial antibodies in a healthy cohort and in TEAMM patients at disease
presentation and 1 year after. Upper panel shows percentage protected for each of 12 separate pneumococcal serotypes. Lower panel shows percentages
protected against at least 8/12, 6/12 and 4/12 pneumococcal serotpyes, 4 meningococcal serotypes, haemophilus, tetanus and diphtheria toxoids.
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Pn1, 3, and 4 were the most suppressed with <10% of
myeloma patients showing the minimum level required
for protection. The only serotype with adequate protec-
tion was Pn14, with 60% of patients achieving the
threshold of ≥0.35 µg/ml and the only bacterial antigen
out of all 19 investigated with more than half of patients
protected. Only 6% of myeloma patients had protective
levels for 2/3rd of pneumococcal serotypes compared
with 55% of healthy donors. Protective levels for half and a
third of pneumococcal serotypes, respectively, were 15%
and 33% in myeloma patients compared to 6%7 and 80%
for healthy controls. The highest level of protection for
the healthy donors was found for tetanus toxoid, where
95% of individuals displayed protective levels in contrast
to 41% of myeloma patients. A positive correlation was
found between levels of polyclonal IgG (r= 0.96) and IgM
(r= 0.84) at presentation and the numbers of bacterial
serotypes for which specific antibody levels were protec-
tive (Fig. 4).
Antibody protection against bacterial antigens was found
to differ between patients under 65 and greater or equal to
65 years old (Table 2). A higher proportion of younger
myeloma patients had protective levels against Haemo-
philus, Meningococcal serotypes, Tetanus and Diphtheria
toxoids. Conversely, a higher proportion of older patients
had protective levels against pneumococcal serotypes.
Fig. 3 Anti-bacterial serum antibody levels in TEAMM patients at diagnosis and 1 year post-diagnosis compared with protective thresholds.
Distribution of anti-bacterial antibody concentrations quantified at disease presentation (baseline) and after 1 year in TEAMM patients (n= 322). The
median for each antibody concentration is shown in black and the recommended IgG concentrations for protection against each bacteria is presented as
discontinuous lines: 0.35 μg/ml for pneumococcal (Pn) polysaccharide, 2.0 μg/ml for meningococcal (Men) polysaccharide, 1.0 μg/ml for Haemophilus
influenzae b (Hib), 0.1 IU/ml for tetanus and diphtheria antigens. Percentage reduction between median levels at presentation and at 1 year is shown.
Statistical significance was calculated using the Wilcoxon test and is shown for each pair of data (*p < 0.5; **p < 0.01; ***p < 0.001; ns p< 0.5).
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By 1 year IgG antibodies against protein antigens have
changed little and against bacterial polysaccharide
antigens have reduced to lower levels than seen at
diagnosis
Anti-bacterial antibodies were measured in paired
samples from diagnosis and at 1 year for 322 MM
patients. The concentration of antibodies against the 19
bacterial antigens are shown in Fig. 3 and comprise the
two thymus-dependent protein antigens tetanus and
diphtheria toxoids and the seventeen thymus independent
polysaccharide antigens, haemophilus, 4 meningococcal
serotypes and 12 pneumococcal serotypes. For the two
protein antigens there was no significant difference in
overall concentrations of IgG anti-toxoid antibodies
between baseline and 1 year (Fig. 3), although antibody
median titres were significantly increased at 1 year com-
pared to baseline for both toxins when patients were
divided by treatment in TE and TNE (30% in TNE and
63% in TE for tetanus and 100% in TNE and 33% in TE
for diphtheria (Fig. S2)). No significant differences were
identified in the levels of anti-toxoid antibodies at baseline
between TE and TNE (p= 0.17 for tetanus and p= 0.11
for diphtheria), while anti-tetanus levels were 44% higher
at 1 year in TE patients compared to TNE (Fig. S2). There
was no difference in the proportions of patients protected
at baseline and 1 year for tetanus (53 and 52%) or diph-
theria (32 and 30%) toxins (Fig. 2). In contrast levels of
antibody against polysaccharide antigens fell by a year
both as median titres (Fig. 3) and proportion of patients
protected (Fig. 2). For haemophilus and meningococcal C,
W and Y serotypes most patients had antibody levels
50–100 times lower than the protective threshold and
there was little difference between diagnosis and a year.
For meningococcal A and the pneumococcal serotypes
there was a reduction in antibodies between diagnosis and
a year. There were significant reductions in IgG titres
between diagnosis and a year for pneumococcal serotypes
3, 4, 5, 6b, 7f, 9v, 14, 19a, 19f, and 23f (Fig. 3). The per-
centage of people protected against 4/12 serotypes
reduced from 26 to 15 and for meningococcal A from 14
to 11%. No significant differences were found between
levofloxacin treatment or placebo for antibody levels or
percentage protected at 1 year.
Prediction of time to febrile episode or death within
12 weeks of starting trial treatment
No relationships were found between levels of protec-
tion against the 19 bacterial serotypes and the occurrence
of deaths, febrile infections, non-febrile infections or total
infections in the first 12 weeks from entry to the trial
(Table S2). Cox regression analysis showed that use of
prophylactic septrin was the single most important pre-
dicator of time to febrile episode or death within 12 weeks
of starting trial treatment. Septrin retained significance in
a multivariate model adjusting for baseline factors and
antigens. A cox regression model excluding septrin
identified ECOG performance status as the only factor
with borderline significance (Table S3). Neither poly-
clonal IgM, nor the levels of specific antibody against the
17 polysaccharide and two protein bacterial targets were
significant predicators of febrile episode or death
(Table S3).
Fig. 4 Correlation between polyclonal IgG and IgM with protection against bacterial serotype in TEAMM patients at presentation and
including healthy controls for reference levels. Polyclonal IgG and IgM in a healthy cohort and in TEAMM patients in correlation with their level of
protection against bacterial serotypes. Median levels of polyclonal immunoglobulins are shown in red for each group. Spearman correlation
coefficient is reported for each analysis.
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Discussion
Polyclonal serum IgG, IgA and IgM levels were low at
myeloma diagnosis as we and others have found pre-
viously11–13. This immunoparesis is present in 85% of
patients and is severe. In our previous study we found
immunoparesis, particularly of IgM, associated with
adverse PFS and OS but not strongly associated with
infection and this has been reported by other
groups12,13,25. In the TEAMM study, infection was a
major outcome in the first 12 weeks from diagnosis when
infection is commonest and so this provided a good
platform for more detailed investigation of the utility of
polyclonal immunoglobulin levels for predicting risk of
infection. Further, for the first time, we have been able to
investigate, in a large number of MM patients, specific
titres of antibody against a range of bacterial antigens
(functional antibody) to predict infection and guide use of
management strategies including prophylactic antibiotics.
We show functional antibodies are even more severely
compromised at disease presentation than total polyclonal
antibody levels although the two are correlated.
Levels of functional antibody against the thymus-
dependent antigen tetanus toxoid were the least
impaired with 41% of patients protected vs. 95% of
healthy controls. Following pneumococcal vaccination
achievement of protective levels of antibody against two
thirds of serotypes tested is considered a satisfactory
antibody response. Most of the healthy donors would
not have received a pneumococcal vaccination but by
natural exposure to pneumococci 55% had protective
antibody levels against 8/12 serotypes vs. just 6% of the
myeloma patients.
The proportion of myeloma patients with protective
antibody levels against tetanus toxoid was significantly
lower in older myeloma patients as expected because of
immunosenesence. Conversely, a higher proportion of
older patients had protective levels against pneumo-
coccal serotypes. This may reflect the UK 23-valent
polysaccharide pneumococcal vaccination (PPV23) pro-
gramme for individuals aged above 6526. Although these
findings provide some support for the efficacy of the
current vaccination programme in this age/patient
population, significant differences were only found for 4
pneumococcal serotypes. Further, the majority of older
patients still failed to meet protective levels and only
6.5% of older myeloma patients demonstrated protective
levels for 8/12 or more serotypes. Previous studies have
shown reduced levels of antibody production to PPV23
in MM patients7,27.
Higher proportions of patients were found to experience
infections and febrile episodes when polyclonal IgA and
IgM were severely reduced but not IgG. However, cox
regression analysis showed total polyclonal antibody levels
nor titres of antibody against 19 different bacterial anti-
genic targets predicted infections and deaths in the first
twelve weeks from diagnosis. This may reflect that strati-
fication by immunoparesis at diagnosis is limited because
the great majority of MM patients have severe immuno-
paresis whether assessed by total or specific functional
antibody levels. Additionally, they have a broad and pro-
found immunodeficiency encompassing reduced integrity
of barriers to infection and major deficits in other com-
ponents of adaptive immunity and of innate immunity.
The greater importance of this much broader immuno-
deficiency causal to high infection rates is supported by
lack of efficacy of IgG replacement therapy in newly
diagnosed myeloma. In a double-blind placebo-controlled
Table 2 Percentage of individuals with protective levels
of anti-bacterial antibodies for TEAMM patients < or ≥ 65
years old.
Proportion of individuals with protective
levels of anti-bacterial IgGs
Antigens (protective
threshold)
MM patients Under
65 (n= 335)
MM patients 65 and
over (n= 503)
Pn 1 (≥0.35 µg/ml) 4.6 12.4****
Pn 3 (≥0.35 µg/ml) 4.6 4.1
Pn 4 (≥0.35 µg/ml) 0.9 2.4
Pn 5 (≥0.35 µg/ml) 14.0 23.0**
Pn 6b (≥0.35 µg/ml) 9.7 11.5
Pn 7 F (≥0.35 µg/ml) 38.3 40.6
Pn 9 V (≥0.35 µg/ml) 27.4 31.4
Pn 14 (≥0.35 µg/ml) 58.9 62.3
Pn 18 C (≥0.35 µg/ml) 17.1 31.5****
Pn 19 A (≥0.35 µg/ml) 22.6 27.8
Pn 19 F (≥0.35 µg/ml) 24.6 29.3
Pn 23 F (≥0.35 µg/ml) 13.1 16.0
8/12 Pn Serotypes 4.6 6.5
6/12 Pn Serotypes 10.9 18.4**
4/12 Pn Serotypes 28.6 34.8
Hib (≥1 µg/ml) 22.0 21.0
Tetanus (≥0.1 IU/ml) 46.0 36.7**
Diphtheria (≥0.1 IU/ml) 13.7 13.0
Men A (≥2 µg/ml) 17.7 16.9
Men C (≥2 µg/ml) 1.4 0.2*
Men W (≥2 µg/ml) 1.7 1.1
Men Y (≥2 µg/ml) 4.9 4.3
The italicised values are used to indicate higher percentages of individual with
protective levels between the two age groups. Statistical significance was
calculated using the Chi-square test and is shown for < 65 vs. ≥ 65 years old
myeloma patients (*p < 0.05; **p < 0.01; ***p < 0.001).
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trial in 203 newly diagnosed myeloma patients infusions of
placebo or 18 g human polyclonal IgG on days 1, 8, 22, 43,
64 and 85 from entry to the study did not alter the inci-
dence or type of infections and did not alter hospital
admissions or antibiotic use for infections (MacLennan
ICM personal communication. A Trial of Intravenous
Immunoglobulin Prophylaxis in Myelomatosis for the
MRCWorking Party on Leukaemia in adults. Presented to
the 1993 UK annual review).
There is a gradation of severity of immunoparesis from
Monoclonal Gammopathy of Undetermined Significance
(MGUS) to Smouldering MM and through increasing
severity of MM stages12,17. Accordingly as anti-myeloma
therapy brings patients into remission one might expect a
degree of recovery from immunoparesis particularly as
current myeloma treatments induce complete responses
in higher proportions of patients. Post high-dose mel-
phalan and autologous stem cell transplant about half of
myeloma patients have recovery of normal levels of
polyclonal immunoglobulins and these patients compared
to those with sustained immunoparesis have improved
PFS and OS28–30. We have found the same in our TE
patients and importantly also (we believe for first time)
that TNE patients had a similar recovery of polyclonal
immunoglobulin levels post induction treatment. This
observation is limited in being made at the fixed time
point of 1 year from entry to the trial and not all patients
will have completed their TE or TNE treatments and
reached remission. A further limitation is that the trial did
not extend observations beyond a year and so we have not
been able to assess recovery from immunoparesis as a
prognostic factor for PFS or OS.
Despite substantial recovery of total polyclonal IgG
levels at 1 year in both TE and TNE patients, median titres
and percentage of patients with protective IgG levels did
not increase for tetanus and diphtheria toxins. Further,
levels of specific IgG against bacterial polysaccharides (12
pneumococcal serotypes, 4 meningococcal serotypes and
haemophilus) had fallen from very low levels at diagnosis
to levels, suggesting their immune systems had reverted to
a naive state. For most patients and against most bacterial
antigen targets levels of antibody were 50- to a 100-fold
lower than protective levels.
The findings of this study show that functional antibody
levels against certain pathogens worsens following treat-
ment and does not mirror total immunoglobulin recovery.
Presumably this reflects recovery of humoral immunity
following myeloma therapy being skewed by the antigenic
and cytokine environment at that time and would not
favour recovery of humoral immunity to pathogens to
which the individual was vaccinated against or exposed
against much earlier in life.
In conclusion, these data demonstrate the need to
protect patients against infections at diagnosis, during
anti-myeloma therapy and importantly also during
remission phases. Prophylactic antibiotics and patient
education, should be considered during active disease/
when patients are undergoing therapy. The TEAMM
trial showed a clear benefit for levofloxacin in the first
12 weeks and further studies are needed to identify
optimal prophylaxis (levofloxacin, septrin, or a combi-
nation of both) and the optimal duration for prophylaxis.
Vaccination should be avoided while patients are on
treatment but this study clearly demonstrates the need
for vaccination following treatment: in remission despite
substantial recovery of total polyclonal immunoglobulin
levels patient’s humoral immune system has been ren-
dered naive by the disease and its treatment meaning
they lack protective antibody levels against most bac-
terial antigens.
Current data on vaccination in myeloma is limited and
this study highlights the necessity to determine optimal
vaccination timing and need for booster vaccinations
following treatment. The European Myeloma Network
currently recommendations using a broad spectrum of
vaccinations to overcome severely reduced antibody
titres associated with autologous and particularly allo-
genic transplantation31. However, these guidelines lar-
gely reflect findings in the general/elderly population or
are based on risk of disease. Consequently there is a need
to design and conduct trials to investigate optimal tim-
ing and vaccination strategies in myeloma patients,
specifically in relation to bacteria (such as pneumo-
coccal, mennigocci) and also viruses (influenza) that
pose a high risk to myeloma patients. The efficacy of
vaccination schedules in remission should be considered
and tested for all myeloma patients both in individual
patients through measurement of antibody response to
vaccination and in studies comparing different vaccina-
tion schedules.
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